Comparison studies of ultrasound-guided botulinum toxin injection and balloon catheter dilatation in the treatment of neurogenic cricopharyngeal muscle dysfunction

2021 ◽  
pp. 1-11
Author(s):  
Shuo Luan ◽  
Shao-Ling Wu ◽  
Ling-Jun Xiao ◽  
Hai-Yun Yang ◽  
Mei-Xin Liao ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Balloon Dilatation ◽  
Botulinum Toxin Injection ◽  
Botulinum Toxin Type A ◽  
Balloon Catheter ◽  
Botulinum Toxin Type ◽  
Muscle Dysfunction ◽  
Ultrasound Guided ◽  
Main Effect ◽  
Catheter Dilatation

BACKGROUND: Cricopharyngeal muscle dysfunction (CPD) management has been challenging in clinical practice. OBJECTIVE: To compare the efficacy and safety of ultrasound-guided botulinum toxin injection and balloon catheter dilatation in treating CPD. METHODS: Forty patients with CPD were randomly divided into two groups, namely the botulinum toxin injection group (BTX group) and balloon dilatation group (BD group). Patients in the BTX group received a single ultrasound-guided injection of 50 units of botulinum toxin type A, while the BD group received dilatation therapy five times per week, consecutively for two weeks. Relative opening percentage of the upper esophageal sphincter (UES), the penetration-aspiration scale (PAS), and the Dysphagia Outcome Severity Scale (DOSS) were evaluated by a videofluoroscopic swallowing study (VFSS) at baseline, 1-month, and 3-months posttreatment. The Functional Oral Intake Scale (FOIS) and Standardized Swallowing Assessment (SSA) were also used to evaluate participants’ swallowing function at baseline and the 1-week, 2-week, 1-month, and 3-month follow-ups. RESULTS: A generalized estimating equation (GEE) model revealed the significant main effect for time in UES, PAS, DOSS, FOIS, and SSA compared to baseline (P <0.05), while no group-by-time interactions (except for the PAS assessment) or main effect for treatment was detected among the above multiple variances. No systematic complications or severe adverse effects were noted. CONCLUSION: Both ultrasound-guided botulinum toxin type A injections and balloon dilatation therapy have been proven as safe and effective treatments for CPD patients. Future clinical trials with longer follow-up periods and more participants are warranted.

scholarly journals Ultrasound guided injections of botulinum toxin type A into stellate ganglion to treat insomnia

2017 ◽  
Vol 14 (2) ◽  
pp. 1136-1140
Author(s):  
Xu-Dong Ding ◽  
Zhi-Gang Ding ◽  
Wei Wang ◽  
Yan-Ping Liu ◽  
Jing Zhong ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Stellate Ganglion ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Ultrasound Guided

Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache

2008 ◽  
Vol 123 (4) ◽  
pp. 412-417 ◽  
Author(s):  
J A de Ru ◽  
J Buwalda
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Injection ◽  
Botulinum Toxin Type A ◽  
Effective Means ◽  
Case Series ◽  
Botulinum Toxin Type ◽  
Toxin A ◽  
Tertiary Referral Centre ◽  
Corrugator Supercilii

AbstractObjective:To describe our results with botulinum toxin type A injection for headache in carefully selected patients, and to present the rationale behind this therapy.Setting:Tertiary referral centre.Patients and methods:This article describes a case series of 10 consecutive patients with frontally localised headache, whose pain worsened when pressure was applied at the orbital rim near the supratrochlear nerve. The patients received a local anaesthetic nerve block with Xylocaine 2 per cent at this site. If this reduced the pain, they were then offered treatment with botulinum toxin.Intervention:Injection with 12.5 IU of botulinum toxin A into the corrugator supercilii muscle on both sides (a total of 25 IU).Main outcome measure:Pain severity scoring by the patients, ranging from zero (no pain) to 10 (severe pain) on a verbal scale.Results:Following injection, all patients had less pain for approximately two months. This treatment did not appear to have lasting side effects.Conclusion:Xylocaine injection is a good predictor of the effectiveness of botulinum toxin injection into the corrugator muscle as treatment of frontally localised headache. We hypothesise that this pain is caused by entrapment of the supratrochlearis nerve in the corrugator muscle. Furthermore, we found botulinum toxin injection to be a safe and effective means of achieving pain relief in this patient group.

Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma

2007 ◽  
Vol 122 (8) ◽  
pp. 824-828 ◽  
Author(s):  
E J Damrose ◽  
J F Damrose
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Botulinum Toxin Type A ◽  
Tertiary Care ◽  
Voice Quality ◽  
Vocal Folds ◽  
Botulinum Toxin Type ◽  
Care Hospital ◽  
Percutaneous Injection ◽  
Vocal Process

AbstractObjective:This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas.Study design and setting:Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.Results:All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.Conclusions:Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined.Significance:Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.

Subcutaneous Botulinum Toxin Injection for Post-Thoracotomy Pain Syndrome in Palliative Care: A Case Report

2017 ◽  
Vol 35 (3) ◽  
pp. 511-513 ◽  
Author(s):  
Saima Rashid ◽  
Amanda R. Fields ◽  
Steven J. Baumrucker
Keyword(s):  
Botulinum Toxin ◽  
Symptom Management ◽  
Pain Control ◽  
Clostridium Botulinum ◽  
Botulinum Toxin Injection ◽  
Botulinum Toxin Type A ◽  
Pain Syndrome ◽  
Botulinum Toxin Type ◽  
Improve Symptom ◽  
Traumatic Neuropathy

Post-thoracotomy pain syndrome (PTPS) is a traumatic neuropathy that can affect as many as 50% of patients undergoing thoracotomy. Patients are often refractory to conservative management and may require multiple analgesics for adequate pain control. Botulinum toxin, derived from Clostridium botulinum, has many uses in treating conditions involving spasticity, dystonia, chronic migraine, and a variety of pain disorders including neuropathies. Botulinum toxin type A injections may provide an alternative or adjunct to improve symptom management in patients with PTPS.

Safety of ultrasound-guided botulinum toxin type A injections for patients with anticoagulant and antiplatelet background medication

2019 ◽  
Vol 20 (2) ◽  
pp. 66-69
Author(s):  
Marius-Nicolae Popescu ◽  
◽  
Luminiţa Dumitru ◽  
Matei Teodorescu ◽  
Alina Iliescu ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Ultrasound Guided

Pain and Muscles Properties Modifications After Botulinum Toxin Type A (BTX-A) and Radial Extracorporeal Shock Wave (rESWT) Combined Treatment

2019 ◽  
Vol 19 (8) ◽  
pp. 1127-1133 ◽  
Author(s):  
Megna Marisa ◽  
Marvulli Riccardo ◽  
Farì Giacomo ◽  
Gallo Giulia ◽  
Dicuonzo Franca ◽  
...  
Keyword(s):  
Shock Wave ◽  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Botulinum Toxin Type A ◽  
Combined Treatment ◽  
Extracorporeal Shock Wave Therapy ◽  
Botulinum Toxin Type ◽  
Post Stroke ◽  
Extracorporeal Shock Wave ◽  
Group B

Background and Objective:Spasticity (most common disability in upper motor neuron syndrome or UMNS) caused an inability of patients’ to perform daily activities and a decrease inquality of life. One of the promising methods nowadays, but still not widely used in everyday practice, for spasticity reduction is extracorporeal shock wave. The aim of this study was to evaluate the objective clinical effects of combined treatment botulinum toxin type A and radial Extracorporeal Shock Wave Therapy in spasticity post stroke.Methods:We considered 30 subjects (14 female and 16 male) with post stroke spasticity of Biceps Brachii, Superficial Flexor Digitorum, Gastrocnemius Medialis and Lateralis and we divided patients into two groups (group A received botulinum toxin injection and physiotherapy while group B received botulinum toxin injection, rESWT and physiotherapy). Assessments were performed before treatment (t0), after 1 (t1), 2 (t2) e 3 (t3) months using Modified Ahworth Scale, Visual Analogical Scale for pain and MyotonPro® device (to assessed myometric evaluation of muscles tone and stiffness).Results:Visual Analogical Scale, Modified Ahworth Scale, muscles tone and stiffness statistically decreased until t3 in the group A and in the group B, but the differences between the two groups were significant at the t1 only.Conclusion:Radial Extracorporeal Shock Wave Therapy could be an effective physical treatment aimed at the reduction of upper and lower limbs spasticity and could lead to the improvement of trophic conditions of the spastic muscles in post-stroke.

Sign in / Sign up

Export Citation Format

Share Document